News
-
SpliSense has announced results from the Phase 2 SPL84-002 study of SPL84 inhaled antisense oligonucleotide (ASO) for the treatment of people with cystic fibrosis who carry the 3849+10 Kb C->T mutation in the CFTR gene. The… Read more . . .
-
According to SoftOx Solutions, the company intends to conduct a Phase 1 proof-of-concept dose escalation study of SoftOx inhalation solution (SIS) in cystic fibrosis patients as part of a refocus away from development of SIS… Read more . . .
-
United Therapeutics announced that the Phase 3 TETON-2 trial of nebulized Tyvaso treprostinil inhalation solution in patients with idiopathic pulmonary fibrosis met its primary efficacy endpoint, demonstrating a 95.6 mL change in absolute FVC from baseline to… Read more . . .
-
Inhaled epinephrine developer De Motu Cordis (DMC) announced that its CEO Peter O’Neill has stepped down and that Chief Financial Officer John Corbett will serve as Interim CEO. The company says that it is preparing… Read more . . .
-
Australian inhaled drug developer InhaleRx announced that it has received approval from the Bellberry Human Research Ethics Committee for a Phase 1 trial of its IRX-616a MDI, which the company is developing for the treatment… Read more . . .
-
According to MannKind Corporation, United Therapeutics has exercised an option granted under a 2018 licensing and collaboration agreement between the companies for development of an additional dry powder inhalation product based on MannKind’s Technosphere technology. The… Read more . . .
-
Krystal Biotech, which has been developing both injectable and inhaled formulations of its KB707 gene therapy for the treatment of solid tumors, announced that it will now focus on the inhaled therapy for the treatment… Read more . . .
-
According to BiomX, the FDA has placed a clinical hold on the company’s recently-initiated Phase 2b trial of BX004 inhaled phage cocktail in cystic fibrosis patients with chronic P. aeruginosa lung infections. BiomX said that the… Read more . . .
-
According to Boston-based CILA Therapeutics, the company has been awarded an SBIR Phase 1 grant worth almost $380,000 through the NIH’s National Center for Advancing Translational Sciences (NCATS) for pre-clinical development of the company’s CIL-Key… Read more . . .
-
Firebrick Pharma announced that the European Patent Office has accepted the company’s patent application covering the use of povidone-iodine nasal sprays, including Firebrick’s Nasodine, for the reduction of viral load of SARS-CoV-2 in the nose… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden